期刊文献+

PET imaging in ischemic cerebrovascular disease:current status and future directions 被引量:10

PET imaging in ischemic cerebrovascular disease:current status and future directions
原文传递
导出
摘要 Cerebrovascular diseases are caused by interruption or significant impairment of the blood supply to the brain, which leads to a cascade of metabolic and molecular alterations resulting in functional disturbance and morphological damage. These pathophysiological changes can be assessed by positron emission tomography (PET), which permits the regional measurement of physiological parameters and imaging of the distribution of molecular markers. PET has broadened our understanding of the flow and metabolic thresholds critical for the maintenance of brain function and morphology: in this application, PET has been essential in the transfer of the concept of the penumbra (tissue with perfusion below the functional threshold but above the threshold for the preservation of morphology) to clinical stroke and thereby has had great impact on developing treatment strategies. Radioligands for receptors can be used as early markers of irreversible neuronal damage and thereby can predict the size of the final infarcts; this is also important for decisions concerning invasive therapy in large ("malignant") infarctions. With PET investigations, the reserve capacity of blood supply to the brain can be tested in obstructive arteriosclerosis of the supplying arteries, and this again is essential for planning interventions. The effect of a stroke on the surrounding and contralateral primarily unaffected tissue can be investigated, and these results help to understand the symptoms caused by disturbances in functional networks. Chronic cerebrovascular disease causes vascular cognitive disorders, including vascular dementia. PET permits the detection of the metabolic disturbances responsible for cognitive impairment and dementia, and can differentiate vascular dementia from degenerative diseases. It may also help to understand the importance of neuroinflammation after stroke and its interaction with amyloid deposition in the development of dementia. Although the clinical application of PET investigations is limited, this technology had and still has a great impact on research into cerebrovascular diseases. Cerebrovascular diseases are caused by interruption or significant impairment of the blood supply to the brain, which leads to a cascade of metabolic and molecular alterations resulting in functional disturbance and morphological damage. These pathophysiological changes can be assessed by positron emission tomography (PET), which permits the regional measurement of physiological parameters and imaging of the distribution of molecular markers. PET has broadened our understanding of the flow and metabolic thresholds critical for the maintenance of brain function and morphology: in this application, PET has been essential in the transfer of the concept of the penumbra (tissue with perfusion below the functional threshold but above the threshold for the preservation of morphology) to clinical stroke and thereby has had great impact on developing treatment strategies. Radioligands for receptors can be used as early markers of irreversible neuronal damage and thereby can predict the size of the final infarcts; this is also important for decisions concerning invasive therapy in large ("malignant") infarctions. With PET investigations, the reserve capacity of blood supply to the brain can be tested in obstructive arteriosclerosis of the supplying arteries, and this again is essential for planning interventions. The effect of a stroke on the surrounding and contralateral primarily unaffected tissue can be investigated, and these results help to understand the symptoms caused by disturbances in functional networks. Chronic cerebrovascular disease causes vascular cognitive disorders, including vascular dementia. PET permits the detection of the metabolic disturbances responsible for cognitive impairment and dementia, and can differentiate vascular dementia from degenerative diseases. It may also help to understand the importance of neuroinflammation after stroke and its interaction with amyloid deposition in the development of dementia. Although the clinical application of PET investigations is limited, this technology had and still has a great impact on research into cerebrovascular diseases.
出处 《Neuroscience Bulletin》 SCIE CAS CSCD 2014年第5期713-732,共20页 神经科学通报(英文版)
关键词 STROKE DEMENTIA PET brain metabolism brain ischemia stroke dementia PET brain metabolism brain ischemia
  • 相关文献

参考文献121

  • 1World Health Organisation 2008. Burden of Disease Statistics. Geneva: WHO Press.
  • 2Lopez AD. Mathers CD. Ezzati M. Jamison Dr. Murray CJ. Global and regional burden of disease and risk factors. 2001: systematic analysis of population health data. Lancet 2006. 367: 1747-1757.
  • 3Johnston SC. Mendis S. Mathers CD. Global variation in stroke burden and mortality: estimates from monitoring, surveillance. and modelling. Lancet Neurol 2009. 8: 345-354.
  • 4Leary MC, Saver JL. Annual incidence of first silent stroke in the United States: a preliminary estimate. Cerebrovasc Dis 2003.16: 280-285.
  • 5Pakkenberg B. Gundersen HJ. Neocortical neuron number in humans: effect of sex and age. J Comp Neurol 1997.384: 312-320.
  • 6Clarke DO. Sokoloff L. Circulation and energy metabolism of the brain. In: Siegel GJ, Agranoff BW. Albers RW. et al. (Eds.). Basic Neurochemistry: Molecular. Cellular. and Medical Aspects, 6th ed. Philadelphia: Lippincott-Raven.1999: 637- 669.
  • 7Sokoloff L. Energetics of functional activation in neural tissues. Neurochem Res 1999, 24: 321-329.
  • 8Laughlin SB. AUwell D. The metabolic cost of neural information: from fly eye to mammalian cortex. In: Frackowiak RSI, Magistretti PI. Shulman RG, et 81. (Eds.). Neuroenergetics: Relevance for Functional Brain Imaging. Strasbourg: HFSP Workshop XI. 2001: 54-64.
  • 9Dirnagl U. ladecola C. Moskowitz MA. Pathobiology of ischaemic stroke: an integrated view. Trends Neurosci. 1999. 22: 391-397.
  • 10Hossmann KA. Pathophysiological basis of translational stroke research. Folia Neuropathol2009. 47: 213-227.

同被引文献41

引证文献10

二级引证文献67

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部